

# Japan-UK Symposium on children and young people's cancer in Tokyo



## Chair

### Hiroyuki Mano

National Cancer Center  
Japan / Japan Agency for  
Medical Research and  
Development (AMED),  
Japan



### Darren Hargrave

University College London  
Great Ormond Street  
Institute of Child Health,  
United Kingdom



## AMED PS

### Tomoki Naoe

Nagoya Medical Center  
/ Japan Agency for  
Medical Research and  
Development (AMED),  
Japan



## Program

**Date & Time** 02/23/26 Mon 10:00-17:15 (JST)

### 10:00 Opening Session

#### 10:10 Session 1: Policy and Background

**Title 1:** Japan National Cancer Policy and Plan  
Children and Young People's Cancer Research in Japan  
Patient Engagement Landscape in Japan

**Title 2:** Lay Perspective from PPIE Representatives on Priorities and Unmet Needs  
UK National Cancer Plan  
Overview of NIHR and its Funding/Support for Cancer Research

#### 10:30 Session 2: Solid Cancers

**Title 1:** International Collaboration for Liver Tumors

**Title 2:** Other Solid Tumor Trials  
Other UK-Led Platform Trials (UK)  
Inter-Ewing-1 (JP)

**Title 3:** Genomics Informing Clinical Trials

**Title 4:** Next-Generation Genomic Medicine in Pediatric Cancer

#### Moderated Discussion

11:40 Break

#### 11:50 Session 3: Hematological Cancer

**Title 1:** Development of a Non-Viral Gene Delivery Platform for CAR-T Cell Therapy  
in Hematologic Diseases

**Title 2:** UCL CAR-T Cell Therapies for Pediatric Leukaemia

**Title 3:** Novel Agents for Pediatric Leukaemia, Japanese Experience

**Title 4:** Novel Agents for Pediatric Leukaemia, UK Experience

#### Moderated Discussion

13:00 Break

#### 14:00 Session 4: Brain Cancer

**Title 1:** Japanese Patients' Problem

**Title 2:** UK Patient Research Perspective

**Title 3:** Japanese Clinical Trials

**Title 4:** Japanese Basic Research

**Title 5:** UK Clinical Trials

**Title 6:** UK Translational Research

#### Moderated Discussion

15:10 Break

#### 15:20 Session 5: The Wider Research Landscape in Japan and the UK

**Introduction:** UK Research Priorities for Children and Young People

**Title 1:** Making the Most of International Data and Cancer Registries

**Title 2:** 'Living within a Trial' for Children and Young People, Maximising Patient Experience

**Title 3:** What is the Patient Experience

#### Moderated Discussion

#### Summing Up

16:30 Break

#### 16:40 Wrap-Up

#### 17:10 Closing Remarks



## Session 1 : Policy and Background

This session will examine how policy contexts, research ecosystems, funding frameworks, and national priorities are shaping children and young people's cancer research in Japan and the UK, as well as the development of the AMED-NIHR partnership.

From the Japan side, MHLW will present an overview of the Comprehensive 10-Year Strategy for Cancer Control, and AMED will present its funding program, the Practical Research for Innovative Cancer Control. From the UK side, we will firstly hear reflections from a patient and public perspective, before focusing on DHSC and NIHR priorities for and approaches to supporting cancer research.

### Moderator



#### Sakura Tanaka

Japan Agency for Medical Research and Development (AMED), Japan



#### David Linberry

UK Department of Health and Social Care (DHSC), United Kingdom

### Speaker

#### Title 1

Japan National Cancer Policy and Plan  
Children and Young People's Cancer Research in Japan  
Patient Engagement Landscape in Japan



#### Shinya Tsuruta

Director, Cancer and Disease Control Division, Ministry of Health, Labour and Welfare (MHLW), Japan

#### Keizo Horibe

Nagoya Medical Center / Japan Agency for Medical Research and Development (AMED), Japan

#### Junichi Kawata

Patient and Public representatives, Japan

#### Title 2

Lay Perspective from PPIE Representatives on Priorities and Unmet Needs  
UK National Cancer Plan  
Overview of NIHR and its Funding/Support for Cancer Research



#### Claudia Laird

Patient and Public representatives, United Kingdom

#### Alex Brownsdon

Patient and Public representatives, United Kingdom

#### David Linberry

UK Department of Health and Social Care (DHSC), United Kingdom

#### Abbie Fearon

National Institute for Health and Care Research (NIHR), United Kingdom





## Session 2 : Solid Cancers

The solid tumour session will focus particularly on Japan/UK collaboration within clinical trials. We will illustrate a successful example of Japanese/UK collaboration (the PHITT study) and reflect on opportunities and lessons learned. We will present the Japanese/UK collaboration that is in progress to facilitate the opening of the INTEREWING 1 study in Japan and then showcase other UK -led international platform studies. Finally, we will highlight how genomics is informing clinical trial design and entry in both Japan and the UK, drawing on UK genomics infrastructure and JCCG-led genomic initiatives, and discuss future opportunities for alignment and collaboration.

### Moderator



**Tomoro Hishiki**

Chiba University, Japan



**Julia Chisholm**

Royal Marsden Hospital and  
Institute of Cancer Research,  
United Kingdom

### Speaker

#### Title 1

#### International Collaboration for Liver Tumors

**Eiso Hiyama**

Hiroshima University, Japan

**Madhumita Dandapani**

University of Nottingham, United Kingdom



#### Title 2


#### Other Solid Tumor Trials Other UK-Led Platform Trials (UK) Inter-Ewing-1 (JP)

**Lynley Marshall**

The Royal Marsden Hospital & The Institute of Cancer Research, United Kingdom

**Miho Nakajima**

National Cancer Center Japan, Japan



#### Title 3

#### Genomics Informing Clinical Trials

**Aditi Vedi**

University of Cambridge Cambridge University Hospital NHS Foundation Trust, United Kingdom



#### Title 4

#### Next-Generation Genomic Medicine in Pediatric Cancer

**Motohiro Kato**

University of Tokyo, Japan





## **Session 3 : Hematological Cancer**

This session will explore state-of-the-art approaches to pediatric hematological malignancies, with a focus on immunotherapy and novel targeted agents. Speakers from Japan and the UK will compare real-world experience of CAR-T cell therapy for acute leukaemia, spanning clinical outcomes, translational research and future development. Japanese progress in CD19 CAR-T using the piggyBac system will be contrasted with established UCL/UK CAR-T programmes. The session will also review deployment of novel agents in both countries, highlighting practical challenges of access, delivery and equity, and opportunities for deeper Japan-UK collaboration.

### Moderator



**Hideki Muramatsu**

Nagoya University, Japan



**Sara Ghorashian**

University College London Great Ormond Street Institute of Child Health, United Kingdom

### Speaker

#### Title 1

**Development of a Non-Viral Gene Delivery Platform for CAR-T Cell Therapy in Hematologic Diseases**

**Yoshiyuki Takahashi**

Nagoya University, Japan



#### Title 2

**UCL CAR-T Cell Therapies for Pediatric Leukaemia**

**Waseem Qasim**

University College London Great Ormond Street Institute of Child Health, United Kingdom



#### Title 3

**Novel Agents for Pediatric Leukaemia, Japanese Experience**

**Daisuke Tomizawa**

National Center for Child Health and Development, Japan



#### Title 4

**Novel Agents for Pediatric Leukaemia, UK Experience**

**Sara Ghorashian**

University College London Great Ormond Street Institute of Child Health, United Kingdom





## Session 4 : Brain Cancer

This session focuses on pediatric brain tumors, providing a comparative overview of the current landscape in Japan and the UK. We will report on the status of clinical trials, treatment development, and basic research, while highlighting the integral role of Patient and Public Involvement (PPI) in these areas. By discussing the specific challenges and opportunities within both nations, we aim to identify shared priorities. The primary objective is to facilitate a constructive dialogue that leads to the planning and realization of new Japan-UK joint clinical research projects, ultimately accelerating the delivery of better treatments for pediatric and AYA patients.

### Moderator



**Yoshiki Arakawa**

Kyoto University, Japan



**Darren Hargrave**

University College London  
Great Ormond Street Institute  
of Child Health, United  
Kingdom

### Speaker

#### Title 1 Japanese Patients' Problem

**Kyohei Omon**

Patient and Public representatives, Japan



#### Title 2 UK Patient Research Perspective

**Claudia Laird**

Patient and Public representatives, United Kingdom



#### Title 3 Japanese Clinical Trials

**Kai Yamasaki**

Osaka City Hospital Organization, Japan



#### Title 4 Japanese Basic Research

**Koichi Ichimura**

Kyorin University, Japan



#### Title 5 UK Clinical Trials

**Darren Hargrave**

University College London Great Ormond Street Institute of Child Health, United Kingdom



#### Title 6 UK Translational Research

**Chris Jones**

Institute of Cancer Research





## Session 5 : The Wider Research Landscape in Japan and the UK

We will provide a broader overview of the current status and initiatives in collaborative research in pediatric and AYA oncology. We will discuss challenges and future directions for Japan-UK collaboration, focusing on research priorities identified by patients and professionals, and maximising the use of international cancer registry data. Critically, we will discuss how we ensure that children and young people's quality of life is considered/supported within trials. How palliative and oncology teams can work together, ensuring that trials look not only at survival but also at comfort, wellbeing, and the experiences of children, young people and families.

### Moderator



**Daisuke Tomizawa**  
National Center for Child Health and Development, Japan



**Faith Gibson**  
Great Ormond Street Hospital for Children NHS Foundation Trust, United Kingdom



**Lorna Fern**  
University college London Hospitals, United Kingdom

### Speaker

#### Introduction

#### UK Research Priorities for Children and Young People

##### Alex Brownsdon

Patient and Public representatives, United Kingdom

##### Faith Gibson

Great Ormond Street Hospital for Children NHS Foundation Trust, United Kingdom

##### Lorna Fern

University College London Hospitals, United Kingdom



#### Title 1

#### Making the Most of International Data and Cancer Registries

##### Miho Kato

National Center for Child Health and Development, Japan

##### Leila Ellis

University of Bristol, United Kingdom

##### Angela Davey

The University of Manchester, United Kingdom



#### Title 2

#### 'Living within a Trial' for Children and Young People, Maximising Patient Experience

##### Mari Matsuoka

Mie University Graduate School of Medicine, Japan

##### Mika Hirata

Juntendo University, Japan

##### Lucy Coombes

The Royal Marsden NHS Foundation Trust, United Kingdom

##### Helen Pearson

The Royal Marsden NHS Foundation Trust Solving Kids' Cancer UK, United Kingdom



#### Title 3

#### What is the Patient Experience

##### Junichi Kawata

Patient and Public representatives, Japan

##### Claudia Laird

Patient and Public representatives, United Kingdom

##### Alex Brownsdon

Patient and Public representatives, United Kingdom



### Summing Up

**Voting Exercise**  
JLA Prioritisation and Additional Questions  
Strongest Areas for Collaboration

**Faith Gibson**  
**Lorna Fern**  
**Alex Brownsdon**